TOBRADEX ST
LOE Approachingtobramycin / dexamethasone
NDAOPHTHALMICSUSPENSION/DROPS
Approved
Feb 2009
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
5/8 — Partial
TOBRADEX ST (tobramycin / dexamethasone) is corticosteroid hormone receptor agonists [moa]. Approved for inflammatory conditions of the palpebral, bulbar conjunctiva, cornea and 7 more indications. First approved in 2009.
Drug data last refreshed 21h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TOBRADEX ST is a fixed-dose ophthalmic suspension combining tobramycin (antibiotic) and dexamethasone (corticosteroid) for topical ocular use. It treats inflammatory conditions of the anterior eye segment, including conjunctivitis, uveitis, and corneal injuries, by suppressing inflammation while providing antimicrobial coverage. The dexamethasone component works via corticosteroid receptor agonism to inhibit inflammatory mediators and edema.
$0.004BPart D
LOE Approaching1.8 years to LOEWith LOE approaching in 1.9 years and modest Part D spending of $4M, the brand team is in defensive mode, focused on retention rather than growth initiatives.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications (10)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.